Australian researchers have uncovered resistance mutations to Sotrovimab - a monoclonal antibody treatment developed to minimise the risk of severe COVID-19 in patients who have underlying health conditions.
A wide-reaching global review has found that some of the most common pain and fever medicines might increase vulnerability to infections like COVID-19, while others may hold hope for improving our immune response.